# **Wilkes University**

**Laboratory Animal Research Proposal** (Please type your responses into the form and submit additional documents as instructed)

Date:	Expiration Date:				
A. ADMINISTRATIVE DATA					
Department: Principal investigator: WIN:					
Mailing address:					
Phone: Fax:	E-mail:				
Secondary Investigator: Secondary Phone:					
Project title:					
Initial submission: Renewal: If Renewal or Modification please provide original IACUC Proposal	Modification:  Number:				
Funding Source:					
B. ANIMAL REQUIREMENTS					
Genus: [e.g., Mus] Sp	pecies: [e.g., musculus]				
, , , , , , , , , , , , , , , , , , , ,	ommon <i>[e.g., Black6]</i> ame:				
Approximate age, weight or size:					
Sex:					
Bacteriological [e.g., germfree (axenic), defined flora (gnotobiotic), specific pathogen free (SPF), status: conventional]					
Viral status: [e.g., simian immunodeficency virus, simian retrovirus]					
Source(s): [e.g., name of vendor or breeder, or bred in-house]					
Primary housing [Facility manager must certify that facility has the resource capability to support the study. If animals will be housed in lab or anywhere else outside central facility for more than 12 hours, provide building and room number.]					
Location(s) where manipulation will be conducted:					
Number of animals to be used: Year 1: Year 2:	Year 3:				
Total number of animals to be used:					

Please Leave Blank

Proposal #:

Approval Date:

#### C. TRANSPORTATION

Transportation of animals must conform to all institutional guidelines/policies and federal regulations. If animals will be transported on public roads or out of state, describe methods you will use to comply with USDA regulations. If animals will be transported between facilities, describe the methods and containers that will be used. If animals will be transported within a facility, include the route and elevator(s) that will be used.

\_\_\_\_\_

Please coordinate all purchase, shipping, and receipt of research animals via the Wilkes University Biology Lab Manager, Teresa Wasiluk (Teresa.wasiluk@wilkes.edu).

#### D. NARRATIVE DESCRIPTION

Please complete a narrative description of your project that includes the following items. Submit it as an attachment with your IACUC proposal and project protocol.

#### 1. STUDY OBJECTIVES

Briefly explain the aim of the study and why the study is important to human or animal health, the advancement of knowledge, or the good of society in language that a layperson can understand. Please comment on whether the study unnecessarily duplicates other studies.

#### 2. RATIONALE FOR ANIMAL USE

- a. Explain your rationale for animal use. [The rationale should include reasons why it is necessary to use animal models.]
- b. Justify the appropriateness of the species selected. [The species selected should be the lowest possible on the phylogenetic scale.]
- c. Justify the number of animals to be used. [The number of animals should be the minimum number required to obtain statistically valid results. Include justification for group size through a power analysis when possible.]

#### 3. DESCRIPTION OF EXPERIMENTAL DESIGN AND ANIMAL PROCEDURES

- a. Briefly explain the experimental design and specify all animal procedures. All procedures to be employed in the study must be described. This description should allow the IACUC to understand the experimental course of an animal from its entry into the experiment to the endpoint of the study. A flowchart may be an effective presentation of the planned procedure.
- b. A best practice is to provide an acceptable range of the specific items described below to allow flexibility in the use of professional judgment and avoid non-compliance due to work conducted off protocol as a result of overly restricted parameters.

Include the following specific information, if applicable:

- Animal identification methods [e.g., ear tags, tattoos, collar, cage card, implant, etc.].
- **Methods of restraint** [e.g., restraint chairs, collars, vests, harnesses, slings, etc.]. Describe how animals are restrained for routine procedures like blood withdrawals. Prolonged restraint must be justified with appropriate oversight to ensure it is minimally distressing. Describe any sedation, acclimation or training to be used.
- **Experimental injections or inoculations** [substances, e.g., infectious agents, adjuvants, etc.; dose, sites, volume, route, and schedule].
- Blood withdrawals [volume, frequency, withdrawal site, and methodology].
- Radiation [dosage and schedule].

- **Food or fluid restriction** If food, or fluid, or both food and fluid, will be restricted, describe method for assessing the health and wellbeing of the animals. [Amount earned during testing and amount freely given must be recorded and assessed to assure proper nutrition.] If you are seeking a departure from the recommendations of the Guide, provide a scientific justification.
- Pharmaceutical-grade and Non-pharmaceutical-grade Compounds Identify any drugs, biologics, or reagents that will be administered to animals. If these agents are not human or veterinary pharmaceutical-grade substances, provide a scientific justification for their use and describe methods that will be used to ensure appropriate preparation and administration.
- Other procedures [e.g., survival studies, tail biopsies].
- **Resultant effects**, if any, that the animals are expected to experience [e.g., pain or distress, ascites production, etc.].
- Other potential stressors [e.g., noxious stimuli, environmental stress] and procedures to monitor and minimize distress. If a study is USDA Classification E, describe any non-pharmaceutical methods that will be used to minimize pain and distress.
- **Experimental endpoint criteria** [e.g., tumor size, percentage body weight gain or loss, inability to eat or drink, behavioral abnormalities, clinical symptomatology, or signs of toxicity] must be specified when the administration of tumor cells, biologics, infectious agents, radiation or toxic chemicals are expected to cause significant symptomatology or are potentially lethal. List the criteria that will be used to determine when euthanasia is to be performed. Death as an endpoint must be scientifically justified.
- **Euthanasia protocol** Indicate what method will you use to dispatch an animal, list primary and secondary methods.
- **Disposal of animal tissue and specimens** Indicate the procedure for disposing of carcasses and animal tissue. Coordinate with the Biology Lab Manager, Teresa Wasiluk (Teresa.wasiluk@wilkes.edu) for proper containers and procedures.
- **Veterinary care** Indicate the plan of action in case of animal illness [e.g., initiate treatment, call investigator prior to initiating treatment, euthanize].
- Surgical procedures [provide details of survival and non-survival surgical procedures].

#### If surgery is proposed, complete the following and include in Narrative Description:

- 1. Identify and describe the surgical procedure(s) to be performed. Include preoperative procedures [e.g., fasting, analgesic loading], and monitoring and supportive care during surgery. Include the aseptic methods to be used.
- 2. Identify the individual(s) that will perform surgery and their qualifications, training, and/or experience.
- 3. Identify the location where surgery will be performed. [building(s) and room(s)]
- 4. If survival surgery, describe postoperative care that will be provided and frequency of observation. Identify the responsible individual(s) and location(s) where care will be provided. [building(s) and room(s)] Include detection and management of postoperative complications during work hours, after hours, weekends and holidays.
- If non-survival surgery, describe how euthanasia will be provided and how death will be determined.
- 6. Are paralytic agents used during surgery? If yes, please describe how ventilation will be maintained and how pain will be assessed.
- 7. Has major or minor survival surgery been performed on any animal prior to being placed on this study? [Major survival surgery penetrates and exposes a body cavity or produces substantial impairment of physical or physiologic functions or involves extensive tissue dissection or transection (such as laparotomy, thoracotomy, craniotomy, joint replacement, or limb amputation)]. If yes, please explain.
- 8. Will more than one survival surgery be performed on an animal while on this study? If yes, please justify.

#### E. PAIN OR DISTRESS CLASSIFICATION AND CONSIDERATION OF ALTERNATIVES

1. Please list pain or distress classification for USDA covered species. See **Appendix 1** for classification definitions and examples.

Species (common		Number of animals used each year			3 years total number of
name)		Year 1	Year 2	Year 3	animals
	<u> </u>	Tot	al number	of animals	

- 2. Explanation for USDA Classification E (**Attachment 1**), must be completed for animals listed in Classification E.
- 3. Consideration of Alternatives should be included in Attachment 1

If any procedures fall into USDA's Classification D or E, causing more than momentary or slight pain or distress to the animals, describe your consideration of alternatives and your determination that alternatives are not available. Delineate the methods and sources used in the search. Database references must include databases searched, the date of the search, period covered, and the keywords used. Alternatives include methods that:

- refine existing tests by minimizing animal distress,
- reduce the number of animals necessary for an experiment, or
- replace whole-animal use with in vitro or other tests.

If you use ascites production to produce antibodies, you must provide the reason for not using an *in vitro* system. Note that you must certify in Section Q.5. that no valid alternative was identified to any described procedures which may cause more than momentary pain or distress, whether relieved or not.

#### F. ANESTHESIA, ANALGESIA, TRANQUILIZATION, OTHER AGENTS

For animals indicated as Classification D, complete the table below. Use additional sheets if necessary. Include the name of the agent(s), the dosage range, route(s) and schedule of administration. Describe tracking and security of controlled drugs (Drug Enforcement Agency requirements).

Agent Name	Min Dosage	Max Dosage	Dosage Route	Frequency of Dosage	DEA tracking info

#### **G. HAZARDOUS AGENTS**

Use of hazardous agents requires the approval of the institutional Biosafety Office/Committee. Attach documentation of approval for the use of recombinant DNA or potential human pathogens.

Haz	ardous Agent	Yes	No	Agent	Date of Biosafety Approval	Tracking #
Radionu	clides					
Biologica	al Agents					
Hazardo Drugs	us Chemicals or					
	inant DNA					
Describe		proced th this	ures re study.	equired for the safe handling and Also describe methods for remo		
	al safety considera		Jactivit	-y.		
[e.g		_		MAL PRODUCTS FOR USE IN plete a form for each product us		Appendix 2.]
2.	Source:			Material Sterile or At	tenuated: Yes	No
		on; HAF	P - Han	r pathogens? (e.g., MAP - Mouse nster Antibody Production, PCR i rs] No		; RAP - Rat
3.	of the animal facilithe best of my known	ity in qu owledge	uestior e the n	Is to be used have not been pase and/or the material is derived to naterial remains uncontaminated pal Investigator	from the original teste	d sample. To
	NETICALLY ENG				pringulations to the ani	mals Doscribo
				consequences of the genetic ma he animals will require.	impulations to the diff	mais. Describe

#### J. FIELD STUDIES

Much of this information is included in the Narrative Description but please be sure to address how animals in the wild will be used, describe how they will be observed, any interactions with the animals, whether the animals will be disturbed or affected, and any special procedures anticipated. Indicate if federal, state, and/or local permits are required and whether they have been obtained, and provide permit numbers.

K.	SPECIAL CONCERNS OR REQUIREMENTS OF THE STUDY  List any special housing, equipment, animal care or any departures from the Guide [e.g., special caging, water, feed, waste disposal, environmental enrichment, etc.].							
L.	ADDITIONAL S	ADDITIONAL STAFF/STUDENT INFORMATION						
	Please list the name project.	ne, WIN, and pho	ne numbers of any staff	and students who will	be working on the			
Na	me	WIN	Cell Number	Department	Staff/Student			
				•				
м.	SUBMIT A PRO	JECT PROTOCO	OL					
			-					
	A project protoco	I should be subm	nitted in addition to the	Narrative Descriptio	n (Section D)			
NI	DDINCIDAL INV	VESTICATOR C	ERTIFICATIONS					
IN.	PRINCIPAL IN	VESTIGATOR C	ERITICATIONS					
	1. I certify that I	have completed t	the institutionally require	d investigator training	g course.			
	Year of Cours	e Attendance:	Location	on: D2L Server				
	<ol> <li>I certify that I have determined that the research proposed herein is not unnecessarily duplicative of previously reported research.</li> <li>I certify that all individuals working on this proposal who are at risk are participating in the</li> </ol>				ecessarily duplicative of			
			king on this proposal who I and Safety Program.	are at risk are partic	cipating in the			
	4. I certify that the	ne individuals liste	ed in Section A. are auth					
	animals under this proposal, have attended the institutionally required investigator training course, and received training in: the biology, handling, and care of this species; aseptic surgical methods an techniques (if necessary); the concept, availability, and use of research or testing methods that limit the use of animals or minimize distress; the proper use of anesthetics, analgesics, and tranquilizers (if necessary); and procedures for reporting animal welfare concerns.							
			d E proposals (see section d the sources and/or dat					
			y procedures described h					
	momentary pa	in or distress, wh	ether it is relieved or not	t.				
	•	will obtain approv	val from the IACUC befor	e initiating any signif	cant changes in this			
	study. 7 I certify that I	will notify the IAC	CUC regarding any unexp	nected study results th	nat impact the animals			
			ess, morbidity or mortalit					
	veterinarian ar	nd the IACUC.	•		-			
	· ·	am familiar with	and will comply with all p	pertinent institutional,	state, and federal rules			
	and policies.							
	<b>Principal Inves</b>	tigator						
	•	~			_			
	Name:		Signature:		Date:			

O. CONCURRENCES			
PROPOSAL NUMBER	_ (leave blank)		
Safety Office/Committee Certification of Rev [Required of all studies that use hazardous a			
Name:	Signature:	Date:	
Biology Lab Manager			
Attending Veterinarian certification of review medications for any painful procedures:	and consultation on proper use of anesthe	etics and pain relieving	
[Required of all studies using surgical proced	dures or pain relieving medications]		
Name:	Signature:	Date:	
Wilkes IACUC attending Veterinarian	ı		
P. FINAL APPROVAL			
Certification of review and approval by the Committee:	Chairperson of the Wilkes Institutional Anim	al Care and Use	
[Chairperson approval granted following a complete review and discussion of proposal and protocol by all members of the IACUC. If questions arise with your proposal you will be given a chance to respond and modify, if necessary, your proposal prior to approval]			
Name:	Signature:	Date:	
Wilkes IACUC Chairperson			
List any attachments here:			

### **Appendix 1** - USDA Classifications and Examples

**Classification B:** Animals being bred, conditioned, or held for use in teaching, testing, experiments, research, or surgery, but not yet used for such purposes.

#### **Examples:**

- Breeding colonies of any animal species (USDA does not require listing of rats, mice, birds) that are handled in accordance with IACUC approval, the *Guide* and other applicable regulations. Breeding colony includes parents and offspring.
- Newly acquired animals that are handled in accordance with IACUC approval and applicable regulations.
- Animals held under proper captive conditions or wild animals that are being observed.

**Classification C:** Animals upon which teaching, research, experiments, or tests will be conducted involving no pain, distress, or use of pain-relieving drugs.

#### **Examples:**

- Procedures performed correctly by trained personnel such as the administration of electrolytes/fluids, administration of oral medication, blood collection from a common peripheral vein per standard veterinary practice [dog cephalic, cat jugular] or catheterization of same, standard radiography, parenteral injections of non-irritating substances.
- Manual restraint that is no longer than would be required for a simple exam; short period of chair restraint for an adapted nonhuman primate.

**Classification D:** Animals upon which experiments, teaching, research, surgery, or tests will be conducted involving accompanying pain or distress to the animals and for which appropriate anesthetic, analgesic, or tranquilizing drugs will be used.

#### **Examples:**

- Surgical procedures conducted by trained personnel in accordance with standard veterinary practice such as biopsies, gonadectomy, exposure of blood vessels, chronic catheter implantation, and laparotomy or laparoscopy.
- Blood collection by more invasive routes such as intracardiac or periorbital collection from species without a true orbital sinus [e.g., guinea pigs].
- Administration of drugs, chemicals, toxins, or organisms that would be expected to produce pain or distress but which will be alleviated by analgesics, anesthetics, tranquilizers, or supportive care.

**Classification E:** Animals upon which teaching, experiments, research, surgery, or tests will be conducted involving accompanying pain or distress to the animals and for which the use of appropriate anesthetic, analgesic, or tranquilizing drugs will adversely affect the procedures, results, or interpretation of the teaching, research, experiments, surgery, or tests.

#### **Examples:**

- Procedures producing pain or distress unrelieved by analgesics such as toxicity studies, microbial virulence testing, radiation sickness, and research on stress, shock, or pain.
- Surgical and postsurgical sequella from invasion of body cavities, orthopedic procedures, dentistry or other hard or soft tissue damage that produces unrelieved pain or distress.
- Negative conditioning via electric shocks that would cause pain in humans.
- Chairing of nonhuman primates not conditioned to the procedure for the time period used.

**NOTE REGARDING CLASSIFICATION E:** An explanation of the procedures producing pain or distress in these animals and the justification for not using appropriate anesthetic, analgesic or tranquilizing drugs must be provided on **Attachment 1**. This information is required to be reported to the USDA, will be available from USDA under the Freedom of Information Act (FOIA), and may be publicly available through the Internet via USDA's website.

Attachment 1 - Explanation for USDA Classification E
[MUST be typed and is required to accompany USDA Form 7023 to support any USDA Class E listings.]
Name of investigator:
Animal study proposal title:
Species and number of animals listed in Classification E for each year:
Species: Number of animals: year 1 - year 2 - year 3 - Total:
Description of project including reason(s) for species selection:
<b>CLASS E ANIMALS:</b> Provide a scientific justification to explain why the use of anesthetics, analgesics, sedatives or tranquilizers during and/or following painful or distressing procedures is <i>contraindicated</i> :
sedatives of tranquilizers during and/or following painful of distressing procedures is contraindicated.
Consideration of Alternative techniques or methods:
Method of Euthansia:

Signature of investigator:

Signature of IACUC Chairperson:

Date:

Date:

## Appendix 2 -

# **BIOLOGICAL MATERIAL/ANIMAL PRODUCTS FOR USE IN ANIMALS**

3.	Specify Material:		
1.	Source:	Material Sterile or Attenuated: Yes No	
	Has the material been tested for pathogonal Antibody Production; HAP - Hamster Antibody	ens? (e.g., MAP - Mouse Antibody Production; RAP - Rat iibody Production, PCR test)	
	Yes [Attach copy of results]	No	
1.	I certify that the tested materials to be used have not been passed through rodent species outside of the animal facility in question and/or the material is derived from the original tested sample. To the best of my knowledge the material remains uncontaminated with rodent pathogens.		
	Initials of Principal Inve	stigator	